ArticleActa diabetologica2026
Clinical utility of 1-h post-load glucose in accelerating diagnosis of type 2 diabetes: a prospective cohort study.
Article in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo quantify the absolute time in months by which the 1-h post-load glucose (1-hPG) criterion advances the diagnosis of type 2 diabetes (T2D).
methodsWe analyzed data from 7,165 adults (≥ 40 years) without T2D at baseline in the Korean Genome and Epidemiology Study (KoGES). Participants were categorized into high (≥ 155 mg/dL) and low (< 155 mg/dL) 1-hPG groups and followed for a median of 11.5 years. The primary outcome, incident T2D, was analyzed using Cox proportional hazards models, while differences in time-to-diagnosis were determined through restricted mean survival time (RMST) analysis.
resultsHigh 1hPG was a strong independent predictor for incident T2D (adjusted Hazard Ratio: 2.88; 95% CIs: 2.55 − 3.26). After full adjustment, the high 1-hPG group had a diagnostic lead time of 11.1 months (95% CIs, 9.6 − 12.5) for T2D over a decade compared to the low 1-hPG group. This diagnostic advancement was more notable among individuals with prediabetes, expediting diagnosis by up to 15.9 months, and was consistent across sociodemographic factors and comorbidity subgroups.
conclusionHigh 1-hPG advances the diagnosis of T2D by approximately 11 months over a decade, providing quantifiable diagnostic lead time in detecting high-risk individuals. These findings highlight the potential of 1-hPG as a supplementary tool to address the limited sensitivity of conventional screening tests. 1-hPG can aid in identifying high-risk individuals, particularly those with prediabetes, for early preventive interventions.
Indexed as
Identifiers
41984242What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.